Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Abstract A subcutaneous formulation of the anti‐CD20 antibody rituximab has been developed. Fixed‐dose subcutaneous rituximab delivers noninferior serum trough concentrations (Ctrough), ensuring similar target saturation and comparable efficacy/safety, to intravenous rituximab, but with simplified a...

Full description

Bibliographic Details
Main Authors:	Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, Nicolas Frey, Candice Jamois
Format:	Article
Language:	English
Published:	Wiley 2021-08-01
Series:	CPT: Pharmacometrics & Systems Pharmacology
Online Access:	https://doi.org/10.1002/psp4.12665

Similar Items

Population pharmacokinetics : model-free approach and nonlinear mixed-effects modelling
by: Gibiansky, Ekaterina
Published: (1999)

Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys.
by: Cheng-Ping Mao, et al.
Published: (2013-01-01)

Yugoslavia in European and Balkan Politics in the Beginning of the Second World War: an Attempt at Maneuvering and It's Failure
by: L. Y. Gibiansky
Published: (2009-08-01)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
by: Delgado Sánchez O, et al.
Published: (2019-11-01)

Rituximab for the treatment of patients with chronic lymphocytic leukemia
by: M Gentile, et al.
Published: (2010-03-01)

Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients
by: Cherie Severson
Published: (2015-07-01)

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
by: Erwin De Cock, et al.
Published: (2016-01-01)

Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
by: Juan Sebastián Galecio, et al.
Published: (2020-08-01)

Comparative efficacy of chronic lymphocytic leukemia treatment with or without rituximab
by: E. A. Zenkova, et al.
Published: (2019-12-01)

Large Granular Lymphocytic Leukemia: A Report of Response to Rituximab
by: Uroosa Ibrahim, et al.
Published: (2017-01-01)

Role of rituximab in first-line treatment of chronic lymphocytic leukemia
by: Jeffrey Bryan, et al.
Published: (2010-12-01)

Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits
by: Drobnjak T, et al.
Published: (2018-07-01)

Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration
by: Rodney R. Walters, et al.
Published: (2021-06-01)

Pharmacokinetics and bioavailability of tulathromycin following intravenous, intramuscular and subcutaneous administrations in healthy rabbits
by: K Abo-El-Sooud, et al.
Published: (2012-01-01)

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
by: Cristina Bagacean, et al.
Published: (2019-01-01)

Rheumatoid arthritis and associated large granular lymphocytic leukemia- successful treatment with rituximab.
by: Ana Raposo, et al.
Published: (2015-10-01)

Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab
by: Theodore-Oklota C, et al.
Published: (2016-09-01)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
by: Steven E. Coutre, et al.
Published: (2018-06-01)

Stevens–Johnson syndrome secondary to rituximab administration in a chronic lymphocytic leukemia patient
by: V. Tomacinschii, et al.
Published: (2020-10-01)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
by: Sara Bravaccini, et al.
Published: (2020-09-01)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
by: Mandrik O, et al.
Published: (2015-08-01)

Subcutaneous Leiomyosarcoma Metastasized to the Lymph Nodes Involved with Small Lymphocytic Lymphoma / Chronic Lymphocytic Leukemia
by: Ayfer KAMALI POLAT, et al.
Published: (2017-09-01)

EFFICACY AND SAFETY OF CLADRIBINE: SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN HAIRY CELL LEUKEMIA PATIENTS
by: Ola Khorshid, et al.
Published: (2015-10-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

The cost-effectiveness of treatment of relapsed/refractory chronic lymphocytic leukemia with a combination of venetoclax and rituximab
by: Alla V Rudakova, et al.
Published: (2019-06-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Type of serum influences the rituximab dependent cytotoxicity and apoptosis of chronic lymphocytic leukemia cells in vitro
by: Ewelina Ziółkowska, et al.
Published: (2012-10-01)

Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
by: Belen Sadaba, et al.
Published: (2014-01-01)

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
by: A. Razzaque Ahmed, et al.
Published: (2018-07-01)

Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia
by: Ana Colado, et al.
Published: (2021-06-01)

Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
by: Regina Pileckyte, et al.
Published: (2019-10-01)

Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia
by: Aleem Aamer
Published: (2008-01-01)

Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab
by: Subhankar Chakraborty, et al.
Published: (2011-03-01)

Validation of Enzyme Immunoassay for Preclinical Pharmacokinetic Trials of Rituximab
by: V. V Pisarev, et al.
Published: (2019-06-01)

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey
by: William H. Baer II, et al.
Published: (2014-05-01)

Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro
by: Ewelina Ziolkowska, et al.
Published: (2014-12-01)

Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia
by: Reslan, Lina
Published: (2010)

Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.
by: Graeme M Doodnaught, et al.
Published: (2017-01-01)

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
by: Francesco Autore, et al.
Published: (2020-06-01)

Isolation Of Acremonium sp. From Subcutaneous Skin Infection Of A Patient With Chronic Lymphocytic Leukemia
by: Sema Keçeli, et al.
Published: (2016-01-01)